Table 1. Descriptive statistics of the items regarding attitudes towards BRCA1/2 genetic testing (InCRisC France, n = 751).
| Item |
Mean |
SD |
Missing n (%) |
Not at all beneficial (0) n (%) |
Slightly beneficial (1) n (%) |
Somewhat beneficial (2) n (%) |
Beneficial (3) n (%) |
Very beneficial (4) n (%) |
|---|---|---|---|---|---|---|---|---|
| In your opinion what are the potential benefits of predictive genetic testing for an unaffected patient in whose family a BRCA1 or BRCA2 mutation has been identified? | ||||||||
| 1. Removal of uncertainty of genetic risk | 2.98 | 0.85 | 38 (5.1) | 8 (1.1) | 31 (4.1) | 124 (16.5) | 357 (47.5) | 193 (25.7) |
| 2. Provision of information for children | 3.09 | 0.71 | 29 (3.9) | 0 (0.0) | 19 (2.5) | 94 (12.5) | 411 (54.7) | 198 (26.4) |
| 3. Provision of information for other family members | 2.95 | 0.80 | 31 (4.1) | 7 (0.9) | 31 (4.1) | 115 (15.3) | 404 (53.8) | 163 (21.7) |
| 4. Provision of information for family planning | 2.57 | 1.04 | 34 (4.5) | 30 (4.0) | 82 (10.9) | 187 (24.9) | 288 (38.3) | 130 (17.3) |
| 5. Access to increased surveillance and screening | 3.49 | 0.64 | 32 (4. 3) | 4 (0.5) | 2 (0.3) | 29 (3.9) | 285 (37.9) | 399 (53.1) |
| 6. Access to clinical trials | 2.36 | 1.01 | 49 (6.5) | 35 (4.7) | 93 (12.4) | 233 (31.0) | 264 (35.2) | 77 (10.3) |
| 7. Greater choices of risk-reducing management options* for patients with a positive test result | 2.88 | 0.95 | 32 (4.3) | 21 (2.8) | 35 (4.7) | 139 (18.5) | 337 (44.9) | 187 (24.9) |
| 8. Potential increase of life expectancy due to increased surveillance | 3.31 | 0.75 | 27 (3.6) | 7 (0.9) | 8 (1.1) | 59 (7.9) | 333 (44.3) | 317 (42.2) |
|
Very low/none (0)
n(%) |
Low (1)
n(%) |
Moderate (2)
n (%) |
High (3)
n (%) |
Very high (4)
n (%) |
||||
| In your opinion the likelihood of the following negative consequences of predictive BRCA1 and BRCA2 testing are …? | ||||||||
| 9. Psychological distress about being identified positive due to the documented increased risk of breast cancer | 3.24 | 0.69 | 16 (2.1) | 4 (0.5) | 4 (0.5) | 73 (9.7) | 385 (51.3) | 269 (35.8) |
| 10. Family conflict about disclosure of test results | 2.00 | 1.01 | 21 (2.8) | 61 (8.1) | 144 (19.2) | 304 (40.5) | 177 (23.6) | 44 (5.9) |
| In your opinion what is the likelihood of potential abuse / misuse of a positive BRCA1 or BRCA2 test result by third parties which would result in… | ||||||||
| 11. …limited employment opportunities | 1.87 | 1.22 | 35 (4.7) | 136 (18.1) | 126 (16.8) | 201 (26.8) | 201 (26.8) | 52 (6.9) |
| 12. …limited life insurance coverage | 2.69 | 1.18 | 34 (4.5) | 66 (8.8) | 42 (5.6) | 122 (16.2) | 308 (41.0) | 179 (23.8) |
| 13. …limited private health insurance coverage | 2.25 | 1.28 | 35 (4.7) | 107 (14.2) | 83 (11.1) | 169 (22.5) | 240 (32.0) | 117 (15.6) |
| 14. …stigmatization as a “healthy ill” person | 2.21 | 1.20 | 30 (4.0) | 90 (12.0) | 91 (12.1) | 214 (28.5) | 232 (30.9) | 94 (12.5) |
|
Strongly disagree (0)
n(%) |
Disagree (1) n (%) |
Agree (2) n (%) |
Strongly agree(3) n (%) |
|||||
| 15.Do you agree or disagree with the following statement: | ||||||||
| The expected health benefits of BRCA1 and BRCA2 testing exceed expected negative consequences by a sufficiently wide margin to justify prescribing the test | 2.18 | 0.67 | 25 (3.3) | 14 (1.9) | 69 (9.2) | 414 (55.1) | 229 (30.5) | |
* prophylactic mastectomy/oophorectomy